Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $117.76.
• Following the exercise, the reporting person sold all 10,000 shares in multiple tranches on June 4, 2026.
• The sales were executed at weighted average prices ranging from $539.64 to $550.48 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-arranged, automated trading plan, which is standard practice for corporate officers.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 program, which is a standard mechanism for corporate insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction results in a reduction of the CFO's direct equity stake in the company.

Risks

• None identified; this is a routine insider transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice among biotechnology executives to manage personal liquidity and diversify portfolios, and it generally does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives at major biotech firms like Amgen, Gilead, and Biogen to ensure compliance with SEC regulations during share divestment.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and executed via a 10b5-1 plan.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, Rule 10b5-1